Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kin Meds vs NativeMed

Kin Meds
Graded #75

Higher grade

vs+6.400000000000006
NativeMed
Graded #191

Lower grade

The verdict

Kin Meds takes it — 72.9/100 to 66.5/100.

Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
74
74
Dose & formulationKin Meds +29
93
64
Clinical oversightEven
74
74
Labs & monitoringEven
53
53
FulfillmentKin Meds +5
72
67
Contract termsEven
55
55
Kin Meds · left barNativeMed · right bar

The numbers

MetricKin MedsNativeMed
WeighScore72.9/10066.5/100
GradeCC
Scorecard rank#75#191
Semaglutide$149/mo (brand Wegovy)$149/mo (promotional rate, compounded)
Tirzepatide$149/mo (brand Zepbound)$183/mo (promotional rate, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Kin Meds

Graded #75 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described
NativeMed

Graded #191 · C

Strengths

  • LegitScript Certified (verifiable in the footer)
  • Promotional pricing shown publicly: $149/mo semaglutide, $183/mo tirzepatide
  • Online questionnaire intake, with a live visit added when state law requires it

Where it loses points

  • Pharmacy partners aren't named — described only as 'USA-based' or 'accredited' pharmacies
  • States served aren't listed publicly
  • Prices are promotional — confirm whether they hold past month one or rise to the $299/$399 regular rate

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard